Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

AKYA 10.28.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-14
Name of Upcoming Event:Earnings Call
Full Press ReleaseSEC FilingsOur AKYA Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
  • 12.10.2024 - Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
  • 12.09.2024 - Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

Recent Filings

  • 01.16.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
  • 01.16.2025 - 425 Prospectuses and communications, business combinations
  • 01.10.2025 - EX-99.1 EX-99.1
PDF Version

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required toregister online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website athttps://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCodeTM Panels and PhenoCycler®, PhenoImager®Fusion and PhenoImager HT Instruments. To learn more about Akoya, visitwww.akoyabio.com.

Investor Contact:Priyam Shahinvestors@akoyabio.comMedia Contact:Christine Quernmedia@akoyabio.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com